Mitsuhiko Osaki
- Cancer Research top 0.5%
- MicroRNA in disease regulation 12
- Cancer, Hypoxia, and Metabolism 11
- Geriatrics and Gerontology top 0.5%
- Molecular Biology top 1%
- RNA Interference and Gene Delivery 16
- CRISPR and Genetic Engineering 11
- Angiogenesis and VEGF in Cancer 11
- Pluripotent Stem Cells Research 11
- Genetics top 2%
- Oncology top 2%
- Cancer-related Molecular Pathways 18
-
- Inflammatory mediators and NSAID effects 10
Mitsuhiko Osaki
154 papers receiving 6.7k citations
Hit Papers
Peers
Comparison fields: 5 of 128
- Cancer Research 1.8k
- Geriatrics and Gerontology 409
- Molecular Biology 4.1k
- Genetics 533
- Oncology 1.3k
Countries citing papers authored by Mitsuhiko Osaki
This map shows the geographic impact of Mitsuhiko Osaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitsuhiko Osaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitsuhiko Osaki more than expected).
Fields of papers citing papers by Mitsuhiko Osaki
This network shows the impact of papers produced by Mitsuhiko Osaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitsuhiko Osaki. The network helps show where Mitsuhiko Osaki may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mitsuhiko Osaki, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 0 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 0 | |
| 5 | 2023 | 6 | |
| 6 | 2023 | 5 | |
| 7 | 2019 | 13 | |
| 8 | 2019 | 22 | |
| 9 | 2017 | 43 | |
| 10 | 2013 | 19 | |
| 11 | 2013 | 5 | |
| 12 | 2013 | 1 | |
| 13 | 2008 | 84 | |
| 14 | 2008 | 25 | |
| 15 | 2007 | 25 | |
| 16 | 2007 | 167 | |
| 17 | 2007 | 23 | |
| 18 | A selective cyclooxygenase-2 inhibitor, NS398, inhibits cell growth and induces cell cycle arrest in the G2/M phase in human esophageal squamous cell carcinoma cells. | 2004 | 16 |
| 19 | 2001 | 19 | |
| 20 | Expression of growth factors and their receptors in human early colorectal carcinomas: immunohistochemical study. | 1996 | 34 |
About Mitsuhiko Osaki
Mitsuhiko Osaki is a scholar working on Cancer Research, Oncology and Molecular Biology, having authored 158 papers that have together received 6.8k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (18 papers), RNA Interference and Gene Delivery (16 papers), MicroRNA in disease regulation (12 papers), CRISPR and Genetic Engineering (11 papers), Angiogenesis and VEGF in Cancer (11 papers), Pluripotent Stem Cells Research (11 papers), Cancer, Hypoxia, and Metabolism (11 papers) and Inflammatory mediators and NSAID effects (10 papers). The work is most often cited by research in Cancer Research (1.8k citations), Geriatrics and Gerontology (409 citations) and Molecular Biology (4.1k citations). Mitsuhiko Osaki has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Hisao Ito, M Oshimura, Futoshi Okada, Mitsuo Oshimura, Takahiro Ochiya, Fumitaka Takeshita, Toshiaki Inoue, Yusuke Yamamoto, Masaharu Hiratsuka and Nobuaki Kaibara. Their work appears in journals such as Journal of Biological Chemistry, PLoS ONE and Molecular and Cellular Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.